Literature DB >> 26971849

Management of follow-up of neuroendocrine neoplasias.

Ulrich-Frank Pape1, Sebastian Maasberg2, Henning Jann2, René Pschowski2, Sandrine Krüger2, Vikas Prasad3, Timm Denecke4, Bertram Wiedenmann2, Andreas Pascher5.   

Abstract

Neuroendocrine neoplasias (NEN) comprise heterogeneous epithelial neoplasms with a large variety of clinical presentations, treatment options and outcomes. Since potentially all NEN bear malignant potential it is important for long-term clinical management and improvement of outcome to decide on successful and oncologically and economically meaningful follow-up strategies. Evidence-based outcome data validating specific follow-up strategies are, however, not available to date and thus outcome data, known prognostic factors and clinical experience guide the decisions on follow-up regimens. The review summarizes general recommendations as well as specific considerations based on tumor entities, clinicopathological tumor characteristics and clinical experience. Follow-up shall serve the patient to improve outcome, benefit from more effective therapies and suffer less from unnecessary and/or toxic therapeutic interventions and finally preserve or gain a good quality of life.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  follow-up; grading; neuroendocrine neoplasia; outcome; primary tumor; prognosis; quality of life; staging

Mesh:

Year:  2016        PMID: 26971849     DOI: 10.1016/j.beem.2016.02.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  4 in total

1.  Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Simron Singh; David L Chan; Lesley Moody; Ning Liu; Hadas D Fischer; Peter C Austin; Eva Segelov
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

Review 2.  Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?

Authors:  Christian Fottner; Martina Ferrata; Matthias M Weber
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

3.  Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.

Authors:  Hilary Chan; Li Zhang; Michael A Choti; Matthew Kulke; James C Yao; Eric K Nakakura; Mark Bloomston; Al B Benson; Manisha H Shah; Jonathan R Strosberg; Emily K Bergsland; Katherine Van Loon
Journal:  Pancreas       Date:  2021-04-01       Impact factor: 3.243

4.  Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment: A Digestive Endoscopy Society of Tawian (DEST).

Authors:  Chen-Shuan Chung; Cho-Lun Tsai; Yin-Yi Chu; Kuan-Chih Chen; Jung-Chun Lin; Bao-Chung Chen; Wei-Chih Sun; Hsu-Heng Yen; Chiung-Yu Chen; I-Chen Wu; Chao-Hung Kuo; Hisang-Yao Shih; Ming-Jong Bair; Jack P Wang; Wen-Hao Hu; Chang-Shyue Yang; Ming-Lun Han; Tsu-Yao Cheng; Chao-Ming Tseng; Ming-Chang Tsai; Ming-Luen Hu; Hsiu-Po Wang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.